@article{46948bbd4f754a41bdbf78a992c146e1,
title = "Chemotherapy and radiotherapy: Cryptic anticancer vaccines",
abstract = "An attractive, yet hitherto unproven concept predicts that the promotion of tumor regression should elicit the host's immune response against residual tumor cells to achieve an optimal therapeutic effect. In a way, chemo- or radiotherapy must trigger {"} danger signals{"} emitted from immunogenic cell death and hence elicit {"} danger associated molecular patterns{"} to stimulate powerful anticancer immune responses. Here, based on the recent experimental and clinical evidence, we will discuss the molecular identity of the multiple checkpoints that dictate the success of {"} immunogenic chemotherapy{"} at the levels of the drug, of the tumor cell and of the host immune system.",
keywords = "Cancer, Chemotherapy, Inflammasome, Interferon-γ, Interleukin-1β",
author = "Yuting Ma and Oliver Kepp and Fran{\c c}ois Ghiringhelli and Lionel Apetoh and Laetitia Aymeric and Clara Locher and Antoine Tesniere and Isabelle Martins and Andr{\'e} Ly and Haynes, {Nicole M.} and Smyth, {Mark J.} and Guido Kroemer and Laurence Zitvogel",
note = "Funding Information: The authors are supported by grants from the Ligue Nationale contre le Cancer (G.K. and L.Z.), China Scholarship Council (Y.M.), the Fondation pour la Recherche M{\'e}dicale (to L. Apetoh., G.K., and L.Z.), the European Union (INFLACARE grant), the Association For International Cancer Research (to G.K.), Canc{\'e}rop{\^o}le Ile-de-France, Institut National du Cancer (L.Z. and G.K.), Agence Nationale pour la Recherche (to G.K.), the European Molecular Biology Organization (L. Apetoh.), INSERM (A.T.), and the National Health, National Health and Medical Research Council of Australia and The Victorian Cancer Agency (M.J.S. and N.M.H.).",
year = "2010",
month = jun,
day = "1",
doi = "10.1016/j.smim.2010.03.001",
language = "English",
volume = "22",
pages = "113--124",
journal = "Seminars in Immunology",
issn = "1044-5323",
number = "3",
}